Navigation Links
CardioFocus HeartLight™ Endoscopic Ablation System to be Featured at EHRA EUROPACE 2011

MARLBOROUGH, Mass., June 22, 2011 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight™ Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announced today that its technology will be the subject of several scientific sessions at the upcoming European Heart Rhythm Association (EHRA) EUROPACE 2011 congress, June 26-29 in Madrid, Spain.

HeartLight EAS is a unique catheter ablation technology that incorporates an endoscope and illumination to provide physicians with direct visualization within a beating heart, in real time and without radiation. It features a compliant, dynamically adjustable balloon catheter for improved contact with the pulmonary vein (PV) ostium and utilizes laser energy for more efficient, precise ablation. Recent data has demonstrated that approximately 86% of PVs remained persistently isolated after three months following a single procedure with HeartLight EAS, with 65% of patients achieving durable freedom from AF.

"Clinical results with HeartLight EAS throughout Europe have been very promising, and we are excited to showcase our technology at EUROPACE, where catheter ablation will be a major conference topic," commented Stephen Sagon, President and CEO of CardioFocus, Inc. "We are encouraged by the adoption of the technology by numerous cardiology thought leaders, many of whom are presenting at this congress, and expect to broaden the use of the system in Europe as a new treatment option for atrial fibrillation patients."

The HeartLight technology will be featured in the following EUROPACE 2011 sessions:

  • Mini-Satellite Symposium"Pulmonary vein isolation for atrial fibrillation using the laser balloon endoscopic ablation system," Monday, June 27
    Chaired by Vivek Y. Reddy, MD, of Mount Sinai School of Medicine, New York, USA and featuring presentations by Claudio Tondo, MD, PhD, of Centro Cardiologico Monzino, Milan, Italy and Julian Chun, MD, of Cardioangiologisches Centrum Bethanien, Frankfurt, Germany

  • Abstract Presentation"Is pure visually guided pulmonary vein isolation feasible using an endoscopic ablation system?," Tuesday, June 28
    Examines the use of HeartLight EAS in patients with drug-refractory atrial fibrillation; presented by Melanie Gunawardene, MD of Cardioangiologisches Centrum Bethanien, Frankfurt, Germany

  • Techno Live Sessions: Live Case"Atrial fibrillation ablation using laser balloon technology," Tuesday, June 28
    Presented by Vivek Y. Reddy, MD, of Mount Sinai School of Medicine, New York, USA and Petr Neuzil, MD, of Na Homolce Hospital, Prague, Czech Republic

  • For more information about HeartLight EAS, please visit the CardioFocus booth #D16.

    About CardioFocus, Inc.CardioFocus, Inc. is a medical device manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF). Its novel HeartLight Endoscopic Ablation System for catheter ablation incorporates an endoscope to provide physicians with the capacity to see within the heart, and for the first time, visually direct the application of laser energy to achieve durable pulmonary vein isolation.

    The HeartLight Endoscopic Ablation System received CE Mark in 2009 for the treatment of atrial fibrillation, and is commercially available at leading institutions throughout Europe. The device is investigational in the U.S., with a pivotal study expected to commence in 2011. CardioFocus is headquartered in Marlborough, MA.  For more information on the company and its technology, please visit

    The scientific information discussed in this news release is preliminary and investigative. The CardioFocus HeartLight Endoscopic Ablation System is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the system. Only FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Healthcare professionals should refer to/rely upon FDA-approved labeling for the products, and not the information discussed in this news release.Company Contact:

    Media Contact:Anjie Roldan

    Lisa Cook/Jason Rando Vice President Finance

    (646) 536-7012/7025(508) 658-7237

    SOURCE CardioFocus, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. CardioFocus Endoscopic Ablation System Earns CE Mark to Treat Atrial Fibrillation; US Clinical Investigation Underway
    2. CardioFocus Secures $5M Credit Facility with Silicon Valley Bank
    3. New Studies Support CardioFocus HeartLight™ Endoscopic Ablation Systems Notable Treatment Results for Paroxysmal Atrial Fibrillation
    4. New Studies Highlight Benefits of Coblation(R)-Assisted Procedures in Airway Fire Prevention and Endoscopic Sinus Surgery
    5. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
    6. Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System
    7. Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients
    8. Envisionier Announces the Launch of the endogo(R) HD, a Mobile Medical Imaging Platform for Capturing, Storing, and Sharing Endoscopic Multimedia
    9. ATS Medical Announces First in World Human Robotic Endoscopic Aortic Valve Replacement
    10. Reportlinker Adds Brazil, Russian, Indian and Chinese Markets for Endoscopic Devices 2009 (4 Countries)
    11. Olympic Winner Xiong Ni, Spokesperson for Endoscopic Medicine -- Chinese Minimally Invasive Advanced Technology Top in the World
    Post Your Comments:
    (Date:10/12/2015)... ROSEMONT, Ill. , Oct. 12, 2015  To ... the American Academy of Orthopaedic Surgeons (AAOS) ... increase and improve physician, caregiver and patient education; the ... pain management; and support for more effective opioid abuse ... a member of the AAOS Patient Safety Committee. "The ...
    (Date:10/12/2015)... 12, 2015 --> ... the global vital signs monitoring devices market in its upcoming ... and Opportunity Assessment 2015-2025." The global vital signs monitoring devices ... 9.5% and 9.2% in terms of value and volume, respectively, ... offers major insights in detail in this report. ...
    (Date:10/12/2015)... Oct. 12, 2015   Royal Philips (NYSE: ... pathology, today announced a collaboration with Genomic Health ... provider of genomic-based diagnostic tests, to leverage Philips digital ... its molecular diagnostic testing processes.    ... of patient tissue samples and plays a crucial role ...
    Breaking Medicine Technology:
    (Date:10/13/2015)... ... October 13, 2015 , ... ... of telemedicine programs in communities throughout Georgia, along with affiliate organizations, Alabama Partnership ... for their regional telehealth summits for Fall 2015. , Each of the ...
    (Date:10/13/2015)... FL (PRWEB) , ... October 13, 2015 , ... ... the Driveway Snow Blanket, a snow melting invention that helps people in clearing snow ... billion and will continue to grow at 3.8% per year," says Scott Cooper, CEO ...
    (Date:10/13/2015)... ... October 13, 2015 , ... Breathing ... people do not breathe correctly. According to T’ai Chi (also spelled “Taiji”) and ... to breathe correctly, in concert with the 7,000 year old tradition they teach, ...
    (Date:10/13/2015)... ... October 13, 2015 , ... CVS/pharmacy, the retail division ... for enrolling and serving insurance consumers who do not have a bank account, ... monthly premiums. In “Health Plan Engagement Strategies: The ABCs of Serving Consumers Who ...
    (Date:10/13/2015)... Baltimore, MD (PRWEB) , ... October 13, 2015 ... ... and retailing sustainable and eco-friendly home furnishings and décor, today announced it closed ... growth equity investor. The funds will be used to support the Company’s continued ...
    Breaking Medicine News(10 mins):